Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data For AM211, A Novel Product Candidate For The Treatment Of Respiratory Diseases
Amira Pharmaceuticals, Inc. announced initial positive data from a Phase 1 clinical study of AM211, the company"s oral selective antagonist of the DP2 (also known as CRTH2) receptor.
generic viagra online
New Cortex Study Uncovers How We Recognize What Is True And What Is False
A recent neuroimaging study reveals that the ability to distinguish true from false in our daily lives involves two distinct processes. Previous research relied heavily on the premise that true and false statements are both processed in the left inferior frontal cortex. Carried out by researchers from the Universities of Lisbon and Vita-Salute, Milan, the June Cortex study found that we use two separate processes to determine the subtle distinctions between true and false in our daily lives. Deciding whether a statement is true involves memory; determining one is false relies on reasoning and problem-solving processes. Drugshop to buy zoloft online and other pills.
News of the day
Classifying Antiabortion-Rights Crimes As 'Terrorism' Unnecessary, USA Today Opinion Piece States
Scott Roeder, who is charged with the murder of abortion provider George Tiller, and James von Brunn, who is charged with last week"s shooting death of a Holocaust Memorial Museum guard, "appear to be murderers, not terrorists," Jonathan Turley, a professor of public interest law at George Washington University, writes in a USA Today opinion piece. Although "liberals denounced" the tendency of conservatives to call "every possible crime an act of terrorism" while former President George W. Bush was in office, now that there are antiabortion-rights and anti-Semetic suspects, "there is an insistence that these crimes must be treated as terrorism -- as if to call them "murder" or "hate crimes" would diminish their significance," Turley states. Many people who "kill strangers out of hate for their race or religion or some other association" are "loners or rogue operators who seek to satisfy a blood lust against different groups," Turley contends, noting that classifying a crime as an act of terrorism allows for a different types of prosecution, investigation and punishment. According to Turley, the "term "terrorism" once had a clear meaning before it was used as a point of emphasis to evaluate or distinguish certain crimes." The Bush administration"s broadening of the definition to include "any prosecution that disrupts a "potential" terrorism threat" served to further divert the term from its historical definition, he adds. Now, "many want to see terrorism investigations targeting antiabortion activists and other groups that use violent speech," Turley writes."We do not advance our efforts by classifying every hate crime as terrorism," Turley continues, adding that it would be "the terrorists who will benefit from our lack of focus" in the definition. According to Turley, the "fact is that even an authoritarian nation can do little to stop a determined rogue operator from walking into a church and killing someone like Dr. Tiller." Referring to "someone such as Roeder as a murderer does not diminish the crime or the victim" because "we do not have to call murder "terrorism" to take the crime or its causes seriously," Turley writes (Turley, USA Today, 6/17).
Medical Devices

Avalere Estimates Medicare Part D 'Donut Hole' Will Be Obsolete In 2023

Today"s 65 year old Medicare Part D beneficiary will be 79 when the coverage gap, or "donut hole," is eliminated, says a new analysis of proposed legislation from the House of Representatives released today by Avalere Health. The firm also concludes that although fewer people will fall into the gap from now until 2023, by 2020 some of the sickest Medicare beneficiaries will spend upwards of $16,000 on drugs before reaching catastrophic coverage where the government covers 95% of their drug costs. Using language proposed in the recent House legislation and its own analytic models, Avalere researchers assessed what would happen to the coverage gap over time if the proposed House legislation on this aspect of Medicare Part D were enacted. Among their findings: -- The gap will be eliminated over time, but it will likely take 12 years based on the current House proposal. -- Fewer Medicare beneficiaries will fall into the gap over those 12 years, because the legislation increases the rate at which the initial benefit limit and annual out of pocket threshold grow. Those likely to benefit immediately are those who rely on multiple chronic condition medications and do not take any biologic or specialty drugs. -- The sickest beneficiaries who rely on certain categories of high-cost drug therapies currently get through the coverage gap and into catastrophic coverage after spending approximately $3,000 (based on current thresholds); under this proposal, it may take these beneficiaries thousands of dollars more annually than they are currently spending to reach catastrophic coverage support. "Achieving greater beneficiary protection is clearly a difficult challenge given the construct of the benefit, cost concerns, and the wide variety of patient needs," said Jennifer Snow, a senior manager at Avalere Health. "The proposal we evaluated charts a path toward ending the unpopular donut hole, but does impose burdens on many chronically ill beneficiaries." Avalere researchers point to other areas for future research related to coverage gap policies, including the cost of the proposal to the federal government, how it will affect beneficiary and plan behavior, and profiles of certain types of patients and how they would fare under this new proposal and the use of generic medications under Medicare Part D. Avalere Health


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009